Hemispherx Biopharma (NYSEAMERICAN: HEB)
Hemispherx Biopharma (NYSEAMERICAN: HEB) is headquartered in Ocala, Florida.
The company is a biotechnology company that was founded in 1990. The primary focus at Hemispherx Biopharma is the development of medications for the treatment of cancer. The company’s flagship candidate is known as Ampligen and is being developed as a potential option for ovarian cancer.
Visit the Hemispherx Biopharma investor relations website here.